Hikma Pharmaceuticals

Historical price data

Hikma Pharmaceuticals is a UK-based, publicly traded global pharmaceutical company with a mission to put better health within reach, every day. It has established itself as a leader in injectable medicines and maintains a significant portfolio of generic and branded products across therapeutic areas including oncology, cardiovascular, CNS, and anti-infectives. The company's strategic direction focuses on organic growth, strategic acquisitions, and expanding its presence in key emerging markets, particularly in the MENA region where it has a strong heritage and market leadership.

Vertically integrated manufacturing and R&D infrastructure specializing in the development and production of complex generic pharmaceuticals, particularly sterile injectables, with a focus on bioequivalence and process optimization.

17 drugs in pipeline, 1 in Phase 3

Hikma competes with large global generics firms like Pfizer (Hospira), Fresenius Kabi, and Viatris in injectables, and with Teva and Sandoz in oral generics. Its differentiation is built on a reliable supply chain for critical injectables, expertise in complex formulations, and a dominant, trusted brand presence in the MENA region.